Оценка клинико-экономической эффективности фармакотерапии диабетической полиневропатии


Матвеев Н.В.

Сравнение соотношения “затраты–эффективность” при лечении диабетической полиневропатии тиоктовой кислотой и Актовегином, по данным рандомизированных клинических исследований ALADIN III (1999), SIDNEY (2003), а также исследования
D. Ziegler и соавт. (2009), показало экономическое преимущество применения тиоктовой кислоты при кратковременной терапии (21 день), в то время как при длительной терапии (5–6 месяцев) было продемонстрировано клиническое и экономическое преимущество применения Актовегина.

Литература


1. Ametov A, Barinov A, O, Brien P. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha – lipolic acid: the SYDNEY trial. Diabetes Care 2003;26:770–76.


2. Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991;41:1315–17.


3. Boulton AJM, Gries FA, Jervell JA: Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15:508–14.


4. Comi G. et al. and the Italian Diabetic Nephropathy Committee. The Italian multicenter study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Electroencephalogr Clin Neurophysiol 1999;50:546–52.


5. Dyck P. et al. Prevalence by staged severity of various types of diabetic neuropathy, retin­opathy, and nephropathy in population-based cohort: Rochester Diabetic Neuropathy Study. Neurology 1993;43:817–24.


6. Dyck PJ, Dyck PJB. Diabetic polyneuropathy: section III. In Diabetic Neuropathy. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelphia, W.B. Saunders 1999:255–78.


7. Dyck PJ. Severity and Staging of Diabetic Polyneuropathy in Textbook of Diabetic. Neuropathy 2003:171–77.


8. Dyck PJ: Severity and staging of diabetic polyneuropathy. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme 2003:170–75.


9. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 1997; 20(5):836–43.


10. Franklin GM, Kahn LB, Baxter J, et al. Sensory neuropathy in noninsulin-dependent diabetes mellitus. Am J Epidemiol 1990; 131:633–43.


11. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am. J Med 1999; 107:2–8.


12. Jansen W, Beck E. Treatment of the diabetic polyneuropathy – a controlled double blind study. Die Medizinische Welt 1987; 38:838–41.


13. King H, Aubert R, Herman W. Global burden of diabetes 1995–2025. Diabetes Care 1998; 21:1414–31.


14. MacDonald BK et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123:665–76.


15. Manes Ch, Papazoglou N, et al. Prevalence of Diabetic Neuropathy and Foot Ulceration: Identification of Potential Risk Factors–A Population-Based Study. Wounds 2002; 14(1):11–15.


16. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neu­ropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38:1456–61.


17. Melton LJ III, Dyck PJ. Epidemiology. In Diabetic Neuropathy. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelphia, W.B. Saunders 1999:239–78.


18. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes. New Engl J Med 1995; 333:39–84.


19. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1:168–88.


20. Reljanovic M, Reichel G, Rett K, еt al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999; 31:171–79.


21. Savettieri G, et al. Prevalence of diabetic neu­ropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Neurology 1993; 43:1115–20.


22. Tesfaye S, Chaturvedi N, Simon EM, et al. Vascular Risk Factors and Diabetic Neuropathy. N Eng J Med 2005; 4(352):341–50.


23. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38(6):869–80.


24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treat­ment of diabetes on the development and progression of long-term complications in insu­lin-dependent diabetes mellitus. N Engl J Med 1993; 329(14):977–86.


25. The Diabetes Control and Complications Trial Research Group. The effect of intensive dia­betes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122(8):561–68.


26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treat­ment of Diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993; 70:1009–18.


27. Thomas PK: Classification of the diabetic neuropathies. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme 2003: 175–77.


28. Thomas PK: Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997; 46(2):54–57.


29. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998; 21(3):35–8.


30. Walters DA, Gatling W, Mullee MA, et al. The distribution and severity of diabetic foot disease: A community-based study with comparison to a nondiabetic group. Diabetic Med 1992; 9:354–58.


31. Watkins PJ, Thomas PK. Diabetes mellitus and the nervous system. J Neurol Neurosurg Psychiatry 1998; 65(5):620–32.


32. Young MJ, Boulton AJM, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150–54.


33. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti–oxidant alpha-lipoic acid. A 3-week multicentre randomized conrolled trial (ALADIN study). Diabetologia 1995; 38:1425–33.


34. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant alpha–lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha–Lipoic A in Diabetic neuropathy. Diabetes Care 1999; 22(8):1296–301.


35. Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32(8):1479–84.


36. Ziegler D, Nowak H, Kempler P. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21(2):114–21.


37. Ziegler D, Schatz H, Conrad F, et al. Effects of threatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diab Care 1997; 20:369–73.


38. Zyegler D, Reljanovic M, Mehnert H, et all. Alfa–Lipoic acid in the treatment of diabetic polyneuropathy in Germany current evidence front clinical trails. Exp Clin Endocrinol Diabetes 1999; 107:421–30.


39. Аметов А.С., Моргоева Ф.Э., Строков И.А. Диабетическая энцефалопатия и полинев­ропатия: терапевтические возможности актовегина // РМЖ 2005. № 6.


40. Аметов А.С., Солуянова Т.Н. Место Актовегина в лечении и профилактике сахарного диабета типа 2 // Международный эндокринологический журнал 2007. № 4 (10).


41. Аметов А.С., Солуянова Т.Н. Эффективность актовегина в лечении диабетической полинейропатии // Медицинский совет 2010. № 1–2.


42. Аметов А.С., Строков И.А., Баринов А.Н. и др. Альфа-липоевая кислота в лечении симптомной диабетической полиневропатии: symptomatic diabetic neuropathy (SYDNEY) trial // Фарматека 2004. № 11 (88). С. 69–73.


43. Балаболкин М.И. Эндокринология. М., 1998. 687 с.


44. Борисенко О.В., Воробьев П.А. и др. Проблемы стандартизации в здравоохранении, 2008.


45. Демидова И.Ю., Храмилин В.Н., Игнатова О.Ю. Диабетическая дистальная полинейропатия // Эндокринная хирургия, 2008. № 1. С. 29.


46. Гурьева И.В., Комелягина Е.Ю., Кузина И.В. Диабетическая периферическая сенсомоторная нейропатия. Патогенез, клиника и диагностика. Методические рекомендации. М., 2000. 23 с.


47. Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М., 2000. 227 с.


48. Оруджева С.А., Звягин А.А. Оценка функциональных резервов сердечно-сосудистой системы у больных сахарным диабетом. Опасности анестезии и возмож ности анестезиологического обеспечения больных с гнойно-некротическими формами синдрома диабетической стопы // Новости анестезиологии и реаниматологии, 2006. № 3. С. 1–18.


49. Применение Актовегина у больных сахарным диабетом: Методические рекомендации / Под ред. акад. РАМН В.Г. Кукес. М., 2006. 30 с.


50. Прихожан В.М. Классификация диабетической нейропатии // Пробл. эндокринологии 1987. Т. 33. № 3. С. 79–85.


51. Скворцов В.В. К вопросу о диагностике и лечении диабетической полинейропатии. www.diabet.ru/articles/Sent/Neuro.pdf


52. Строков И.А., Баринов А.Н., Новосадо­ва М.В. и др. Клинические методы оценки тяжести диабетической полиневропатии // Неврологический журнал, 2000. № 5. С. 14–19.


53. Храмилин В.Н, Демидова И.Ю. Диабетическая нейропатия. Методические рекомендации. М., 2003. 30 с.


54. Яворская В.А., Гребенюк А.В. Клинический опыт применения Актовегина в неврологии. 2000.


Похожие статьи


Бионика Медиа